nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—GRIN2A—melanoma	0.638	0.869	CbGaD
Amantadine—ABCB1—melanoma	0.0961	0.131	CbGaD
Amantadine—Nerve paralysis—Vemurafenib—melanoma	0.0195	0.168	CcSEcCtD
Amantadine—Paralysis—Vemurafenib—melanoma	0.00234	0.0201	CcSEcCtD
Amantadine—Paranoid reaction—Carmustine—melanoma	0.00202	0.0174	CcSEcCtD
Amantadine—Cerebration impaired—Temozolomide—melanoma	0.00141	0.0121	CcSEcCtD
Amantadine—Visual acuity reduced—Temozolomide—melanoma	0.0014	0.012	CcSEcCtD
Amantadine—Photosensitivity—Vemurafenib—melanoma	0.00135	0.0116	CcSEcCtD
Amantadine—Hypokinesia—Carmustine—melanoma	0.00127	0.011	CcSEcCtD
Amantadine—Paranoia—Carmustine—melanoma	0.00126	0.0108	CcSEcCtD
Amantadine—Stupor—Carmustine—melanoma	0.00115	0.0099	CcSEcCtD
Amantadine—Aggression—Bleomycin—melanoma	0.00112	0.00964	CcSEcCtD
Amantadine—Disturbance in attention—Temozolomide—melanoma	0.00096	0.00825	CcSEcCtD
Amantadine—Photosensitivity reaction—Vemurafenib—melanoma	0.000932	0.00801	CcSEcCtD
Amantadine—Leukocytosis—Carmustine—melanoma	0.000916	0.00787	CcSEcCtD
Amantadine—Gait disturbance—Carmustine—melanoma	0.000882	0.00757	CcSEcCtD
Amantadine—Gait disturbance—Temozolomide—melanoma	0.000852	0.00732	CcSEcCtD
Amantadine—Urinary incontinence—Carmustine—melanoma	0.000831	0.00714	CcSEcCtD
Amantadine—Depressed level of consciousness—Carmustine—melanoma	0.000831	0.00714	CcSEcCtD
Amantadine—Oedema peripheral—Vemurafenib—melanoma	0.000805	0.00692	CcSEcCtD
Amantadine—Depressed level of consciousness—Temozolomide—melanoma	0.000803	0.0069	CcSEcCtD
Amantadine—Urinary incontinence—Temozolomide—melanoma	0.000803	0.0069	CcSEcCtD
Amantadine—Disorientation—Bleomycin—melanoma	0.0008	0.00687	CcSEcCtD
Amantadine—Coma—Carmustine—melanoma	0.000786	0.00675	CcSEcCtD
Amantadine—Eye disorder—Vemurafenib—melanoma	0.000764	0.00656	CcSEcCtD
Amantadine—Cardiac disorder—Vemurafenib—melanoma	0.000758	0.00651	CcSEcCtD
Amantadine—Mental disability—Carmustine—melanoma	0.000747	0.00642	CcSEcCtD
Amantadine—Angiopathy—Vemurafenib—melanoma	0.000741	0.00637	CcSEcCtD
Amantadine—Mediastinal disorder—Vemurafenib—melanoma	0.000737	0.00633	CcSEcCtD
Amantadine—Alopecia—Vemurafenib—melanoma	0.000722	0.0062	CcSEcCtD
Amantadine—Mental disability—Temozolomide—melanoma	0.000722	0.0062	CcSEcCtD
Amantadine—Malnutrition—Vemurafenib—melanoma	0.000711	0.00611	CcSEcCtD
Amantadine—Lethargy—Dactinomycin—melanoma	0.000681	0.00585	CcSEcCtD
Amantadine—Amnesia—Carmustine—melanoma	0.000665	0.00571	CcSEcCtD
Amantadine—Amnesia—Temozolomide—melanoma	0.000643	0.00552	CcSEcCtD
Amantadine—Liver function test abnormal—Dactinomycin—melanoma	0.000616	0.00529	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000601	0.00517	CcSEcCtD
Amantadine—Ataxia—Carmustine—melanoma	0.000587	0.00505	CcSEcCtD
Amantadine—Anaphylactic shock—Vemurafenib—melanoma	0.000581	0.00499	CcSEcCtD
Amantadine—Dysphagia—Dactinomycin—melanoma	0.000577	0.00496	CcSEcCtD
Amantadine—Liver function test abnormal—Carmustine—melanoma	0.000577	0.00495	CcSEcCtD
Amantadine—Nervous system disorder—Vemurafenib—melanoma	0.000569	0.00489	CcSEcCtD
Amantadine—Ataxia—Temozolomide—melanoma	0.000568	0.00488	CcSEcCtD
Amantadine—Skin disorder—Vemurafenib—melanoma	0.000564	0.00484	CcSEcCtD
Amantadine—Hypotension—Vemurafenib—melanoma	0.000543	0.00466	CcSEcCtD
Amantadine—Dysphagia—Carmustine—melanoma	0.00054	0.00464	CcSEcCtD
Amantadine—Neutropenia—Dactinomycin—melanoma	0.000539	0.00463	CcSEcCtD
Amantadine—Dysphagia—Temozolomide—melanoma	0.000522	0.00448	CcSEcCtD
Amantadine—Sweating increased—Temozolomide—melanoma	0.000508	0.00437	CcSEcCtD
Amantadine—Neutropenia—Carmustine—melanoma	0.000505	0.00434	CcSEcCtD
Amantadine—Decreased appetite—Vemurafenib—melanoma	0.000505	0.00434	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vemurafenib—melanoma	0.000501	0.00431	CcSEcCtD
Amantadine—Fatigue—Vemurafenib—melanoma	0.000501	0.0043	CcSEcCtD
Amantadine—Constipation—Vemurafenib—melanoma	0.000496	0.00426	CcSEcCtD
Amantadine—Lightheadedness—Docetaxel—melanoma	0.000495	0.00425	CcSEcCtD
Amantadine—Pulmonary oedema—Docetaxel—melanoma	0.000492	0.00423	CcSEcCtD
Amantadine—Neutropenia—Temozolomide—melanoma	0.000488	0.00419	CcSEcCtD
Amantadine—Agranulocytosis—Dactinomycin—melanoma	0.00048	0.00412	CcSEcCtD
Amantadine—Photosensitivity reaction—Temozolomide—melanoma	0.000476	0.00409	CcSEcCtD
Amantadine—Body temperature increased—Vemurafenib—melanoma	0.000459	0.00394	CcSEcCtD
Amantadine—Cardiac failure congestive—Docetaxel—melanoma	0.000443	0.0038	CcSEcCtD
Amantadine—Alopecia—Bleomycin—melanoma	0.000438	0.00376	CcSEcCtD
Amantadine—Hallucination—Carmustine—melanoma	0.00043	0.00369	CcSEcCtD
Amantadine—Hypersensitivity—Vemurafenib—melanoma	0.000428	0.00367	CcSEcCtD
Amantadine—Oedema peripheral—Carmustine—melanoma	0.000426	0.00366	CcSEcCtD
Amantadine—Visual disturbance—Docetaxel—melanoma	0.000424	0.00364	CcSEcCtD
Amantadine—Asthenia—Vemurafenib—melanoma	0.000417	0.00358	CcSEcCtD
Amantadine—Visual impairment—Carmustine—melanoma	0.000416	0.00358	CcSEcCtD
Amantadine—Hallucination—Temozolomide—melanoma	0.000416	0.00357	CcSEcCtD
Amantadine—Urinary tract disorder—Temozolomide—melanoma	0.000412	0.00354	CcSEcCtD
Amantadine—Oedema peripheral—Temozolomide—melanoma	0.000411	0.00353	CcSEcCtD
Amantadine—Cardiac failure—Docetaxel—melanoma	0.000411	0.00353	CcSEcCtD
Amantadine—Pruritus—Vemurafenib—melanoma	0.000411	0.00353	CcSEcCtD
Amantadine—Lethargy—Docetaxel—melanoma	0.00041	0.00352	CcSEcCtD
Amantadine—Urethral disorder—Temozolomide—melanoma	0.000409	0.00352	CcSEcCtD
Amantadine—Alopecia—Dactinomycin—melanoma	0.000408	0.0035	CcSEcCtD
Amantadine—Eye disorder—Carmustine—melanoma	0.000404	0.00347	CcSEcCtD
Amantadine—Visual impairment—Temozolomide—melanoma	0.000402	0.00346	CcSEcCtD
Amantadine—Diarrhoea—Vemurafenib—melanoma	0.000397	0.00341	CcSEcCtD
Amantadine—Eye disorder—Temozolomide—melanoma	0.00039	0.00335	CcSEcCtD
Amantadine—Cardiac disorder—Temozolomide—melanoma	0.000388	0.00333	CcSEcCtD
Amantadine—Arrhythmia—Carmustine—melanoma	0.000386	0.00332	CcSEcCtD
Amantadine—Leukopenia—Bleomycin—melanoma	0.000386	0.00331	CcSEcCtD
Amantadine—Dizziness—Vemurafenib—melanoma	0.000384	0.0033	CcSEcCtD
Amantadine—Alopecia—Carmustine—melanoma	0.000382	0.00328	CcSEcCtD
Amantadine—Angiopathy—Temozolomide—melanoma	0.000379	0.00325	CcSEcCtD
Amantadine—Mental disorder—Carmustine—melanoma	0.000379	0.00325	CcSEcCtD
Amantadine—Ataxia—Docetaxel—melanoma	0.000378	0.00324	CcSEcCtD
Amantadine—Mediastinal disorder—Temozolomide—melanoma	0.000376	0.00323	CcSEcCtD
Amantadine—Malnutrition—Carmustine—melanoma	0.000376	0.00323	CcSEcCtD
Amantadine—Liver function test abnormal—Docetaxel—melanoma	0.000371	0.00318	CcSEcCtD
Amantadine—Vomiting—Vemurafenib—melanoma	0.000369	0.00317	CcSEcCtD
Amantadine—Alopecia—Temozolomide—melanoma	0.000369	0.00317	CcSEcCtD
Amantadine—Orthostatic hypotension—Docetaxel—melanoma	0.000367	0.00315	CcSEcCtD
Amantadine—Rash—Vemurafenib—melanoma	0.000366	0.00314	CcSEcCtD
Amantadine—Mental disorder—Temozolomide—melanoma	0.000366	0.00314	CcSEcCtD
Amantadine—Dermatitis—Vemurafenib—melanoma	0.000366	0.00314	CcSEcCtD
Amantadine—Headache—Vemurafenib—melanoma	0.000364	0.00312	CcSEcCtD
Amantadine—Malnutrition—Temozolomide—melanoma	0.000364	0.00312	CcSEcCtD
Amantadine—Leukopenia—Dactinomycin—melanoma	0.00036	0.00309	CcSEcCtD
Amantadine—Confusional state—Bleomycin—melanoma	0.000355	0.00305	CcSEcCtD
Amantadine—Vision blurred—Carmustine—melanoma	0.000355	0.00305	CcSEcCtD
Amantadine—Tremor—Carmustine—melanoma	0.000352	0.00303	CcSEcCtD
Amantadine—Oedema—Bleomycin—melanoma	0.000352	0.00302	CcSEcCtD
Amantadine—Anaphylactic shock—Bleomycin—melanoma	0.000352	0.00302	CcSEcCtD
Amantadine—Dysphagia—Docetaxel—melanoma	0.000347	0.00298	CcSEcCtD
Amantadine—Agitation—Carmustine—melanoma	0.000346	0.00297	CcSEcCtD
Amantadine—Nausea—Vemurafenib—melanoma	0.000345	0.00296	CcSEcCtD
Amantadine—Vision blurred—Temozolomide—melanoma	0.000343	0.00294	CcSEcCtD
Amantadine—Tremor—Temozolomide—melanoma	0.000341	0.00293	CcSEcCtD
Amantadine—Leukopenia—Carmustine—melanoma	0.000337	0.00289	CcSEcCtD
Amantadine—Anorexia—Bleomycin—melanoma	0.000335	0.00288	CcSEcCtD
Amantadine—Agitation—Temozolomide—melanoma	0.000334	0.00287	CcSEcCtD
Amantadine—Hypotension—Bleomycin—melanoma	0.000329	0.00282	CcSEcCtD
Amantadine—Oedema—Dactinomycin—melanoma	0.000328	0.00282	CcSEcCtD
Amantadine—Convulsion—Carmustine—melanoma	0.000326	0.0028	CcSEcCtD
Amantadine—Leukopenia—Temozolomide—melanoma	0.000325	0.0028	CcSEcCtD
Amantadine—Hypertension—Carmustine—melanoma	0.000325	0.00279	CcSEcCtD
Amantadine—Neutropenia—Docetaxel—melanoma	0.000324	0.00279	CcSEcCtD
Amantadine—Palpitations—Temozolomide—melanoma	0.000321	0.00276	CcSEcCtD
Amantadine—Anxiety—Carmustine—melanoma	0.000319	0.00274	CcSEcCtD
Amantadine—Paraesthesia—Bleomycin—melanoma	0.000316	0.00271	CcSEcCtD
Amantadine—Convulsion—Temozolomide—melanoma	0.000315	0.00271	CcSEcCtD
Amantadine—Hypertension—Temozolomide—melanoma	0.000314	0.0027	CcSEcCtD
Amantadine—Dyspnoea—Bleomycin—melanoma	0.000314	0.00269	CcSEcCtD
Amantadine—Anorexia—Dactinomycin—melanoma	0.000313	0.00269	CcSEcCtD
Amantadine—Confusional state—Carmustine—melanoma	0.00031	0.00266	CcSEcCtD
Amantadine—Anxiety—Temozolomide—melanoma	0.000308	0.00265	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000307	0.00264	CcSEcCtD
Amantadine—Oedema—Carmustine—melanoma	0.000307	0.00264	CcSEcCtD
Amantadine—Decreased appetite—Bleomycin—melanoma	0.000306	0.00263	CcSEcCtD
Amantadine—Dry mouth—Temozolomide—melanoma	0.000303	0.0026	CcSEcCtD
Amantadine—Tachycardia—Carmustine—melanoma	0.0003	0.00257	CcSEcCtD
Amantadine—Confusional state—Temozolomide—melanoma	0.000299	0.00257	CcSEcCtD
Amantadine—Anaphylactic shock—Temozolomide—melanoma	0.000297	0.00255	CcSEcCtD
Amantadine—Oedema—Temozolomide—melanoma	0.000297	0.00255	CcSEcCtD
Amantadine—Anorexia—Carmustine—melanoma	0.000293	0.00251	CcSEcCtD
Amantadine—Nervous system disorder—Temozolomide—melanoma	0.000291	0.0025	CcSEcCtD
Amantadine—Feeling abnormal—Bleomycin—melanoma	0.00029	0.00249	CcSEcCtD
Amantadine—Agranulocytosis—Docetaxel—melanoma	0.000289	0.00248	CcSEcCtD
Amantadine—Skin disorder—Temozolomide—melanoma	0.000288	0.00248	CcSEcCtD
Amantadine—Hypotension—Carmustine—melanoma	0.000287	0.00246	CcSEcCtD
Amantadine—Hyperhidrosis—Temozolomide—melanoma	0.000287	0.00246	CcSEcCtD
Amantadine—Decreased appetite—Dactinomycin—melanoma	0.000285	0.00245	CcSEcCtD
Amantadine—Fatigue—Dactinomycin—melanoma	0.000283	0.00243	CcSEcCtD
Amantadine—Anorexia—Temozolomide—melanoma	0.000283	0.00243	CcSEcCtD
Amantadine—Body temperature increased—Bleomycin—melanoma	0.000278	0.00239	CcSEcCtD
Amantadine—Insomnia—Carmustine—melanoma	0.000278	0.00239	CcSEcCtD
Amantadine—Paraesthesia—Carmustine—melanoma	0.000276	0.00237	CcSEcCtD
Amantadine—Urinary tract disorder—Docetaxel—melanoma	0.000274	0.00236	CcSEcCtD
Amantadine—Dyspnoea—Carmustine—melanoma	0.000274	0.00235	CcSEcCtD
Amantadine—Oedema peripheral—Docetaxel—melanoma	0.000274	0.00235	CcSEcCtD
Amantadine—Somnolence—Carmustine—melanoma	0.000273	0.00234	CcSEcCtD
Amantadine—Urethral disorder—Docetaxel—melanoma	0.000272	0.00234	CcSEcCtD
Amantadine—Feeling abnormal—Dactinomycin—melanoma	0.00027	0.00232	CcSEcCtD
Amantadine—Insomnia—Temozolomide—melanoma	0.000268	0.00231	CcSEcCtD
Amantadine—Visual impairment—Docetaxel—melanoma	0.000268	0.0023	CcSEcCtD
Amantadine—Decreased appetite—Carmustine—melanoma	0.000267	0.00229	CcSEcCtD
Amantadine—Paraesthesia—Temozolomide—melanoma	0.000266	0.00229	CcSEcCtD
Amantadine—Gastrointestinal disorder—Carmustine—melanoma	0.000265	0.00228	CcSEcCtD
Amantadine—Dyspnoea—Temozolomide—melanoma	0.000265	0.00227	CcSEcCtD
Amantadine—Somnolence—Temozolomide—melanoma	0.000264	0.00227	CcSEcCtD
Amantadine—Constipation—Carmustine—melanoma	0.000263	0.00226	CcSEcCtD
Amantadine—Dyspepsia—Temozolomide—melanoma	0.000261	0.00224	CcSEcCtD
Amantadine—Eye disorder—Docetaxel—melanoma	0.00026	0.00223	CcSEcCtD
Amantadine—Body temperature increased—Dactinomycin—melanoma	0.000259	0.00223	CcSEcCtD
Amantadine—Hypersensitivity—Bleomycin—melanoma	0.000259	0.00223	CcSEcCtD
Amantadine—Decreased appetite—Temozolomide—melanoma	0.000258	0.00222	CcSEcCtD
Amantadine—Cardiac disorder—Docetaxel—melanoma	0.000258	0.00221	CcSEcCtD
Amantadine—Gastrointestinal disorder—Temozolomide—melanoma	0.000256	0.0022	CcSEcCtD
Amantadine—Fatigue—Temozolomide—melanoma	0.000256	0.0022	CcSEcCtD
Amantadine—Constipation—Temozolomide—melanoma	0.000254	0.00218	CcSEcCtD
Amantadine—Feeling abnormal—Carmustine—melanoma	0.000253	0.00217	CcSEcCtD
Amantadine—Asthenia—Bleomycin—melanoma	0.000252	0.00217	CcSEcCtD
Amantadine—Angiopathy—Docetaxel—melanoma	0.000252	0.00216	CcSEcCtD
Amantadine—Mediastinal disorder—Docetaxel—melanoma	0.00025	0.00215	CcSEcCtD
Amantadine—Pruritus—Bleomycin—melanoma	0.000249	0.00214	CcSEcCtD
Amantadine—Arrhythmia—Docetaxel—melanoma	0.000248	0.00213	CcSEcCtD
Amantadine—Alopecia—Docetaxel—melanoma	0.000245	0.00211	CcSEcCtD
Amantadine—Feeling abnormal—Temozolomide—melanoma	0.000245	0.0021	CcSEcCtD
Amantadine—Mental disorder—Docetaxel—melanoma	0.000243	0.00209	CcSEcCtD
Amantadine—Body temperature increased—Carmustine—melanoma	0.000243	0.00208	CcSEcCtD
Amantadine—Malnutrition—Docetaxel—melanoma	0.000242	0.00208	CcSEcCtD
Amantadine—Hypersensitivity—Dactinomycin—melanoma	0.000242	0.00208	CcSEcCtD
Amantadine—Asthenia—Dactinomycin—melanoma	0.000235	0.00202	CcSEcCtD
Amantadine—Body temperature increased—Temozolomide—melanoma	0.000235	0.00201	CcSEcCtD
Amantadine—Hypersensitivity—Carmustine—melanoma	0.000226	0.00194	CcSEcCtD
Amantadine—Diarrhoea—Dactinomycin—melanoma	0.000224	0.00193	CcSEcCtD
Amantadine—Vomiting—Bleomycin—melanoma	0.000224	0.00192	CcSEcCtD
Amantadine—Rash—Bleomycin—melanoma	0.000222	0.00191	CcSEcCtD
Amantadine—Dermatitis—Bleomycin—melanoma	0.000222	0.0019	CcSEcCtD
Amantadine—Asthenia—Carmustine—melanoma	0.00022	0.00189	CcSEcCtD
Amantadine—Hypersensitivity—Temozolomide—melanoma	0.000219	0.00188	CcSEcCtD
Amantadine—Leukopenia—Docetaxel—melanoma	0.000216	0.00186	CcSEcCtD
Amantadine—Palpitations—Docetaxel—melanoma	0.000214	0.00184	CcSEcCtD
Amantadine—Asthenia—Temozolomide—melanoma	0.000213	0.00183	CcSEcCtD
Amantadine—Diarrhoea—Carmustine—melanoma	0.00021	0.0018	CcSEcCtD
Amantadine—Pruritus—Temozolomide—melanoma	0.00021	0.0018	CcSEcCtD
Amantadine—Convulsion—Docetaxel—melanoma	0.000209	0.0018	CcSEcCtD
Amantadine—Nausea—Bleomycin—melanoma	0.000209	0.00179	CcSEcCtD
Amantadine—Hypertension—Docetaxel—melanoma	0.000209	0.00179	CcSEcCtD
Amantadine—Vomiting—Dactinomycin—melanoma	0.000209	0.00179	CcSEcCtD
Amantadine—Rash—Dactinomycin—melanoma	0.000207	0.00178	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000204	0.00176	CcSEcCtD
Amantadine—Dizziness—Carmustine—melanoma	0.000203	0.00174	CcSEcCtD
Amantadine—Diarrhoea—Temozolomide—melanoma	0.000203	0.00174	CcSEcCtD
Amantadine—Dry mouth—Docetaxel—melanoma	0.000201	0.00173	CcSEcCtD
Amantadine—Confusional state—Docetaxel—melanoma	0.000199	0.00171	CcSEcCtD
Amantadine—Oedema—Docetaxel—melanoma	0.000197	0.00169	CcSEcCtD
Amantadine—Anaphylactic shock—Docetaxel—melanoma	0.000197	0.00169	CcSEcCtD
Amantadine—Dizziness—Temozolomide—melanoma	0.000196	0.00169	CcSEcCtD
Amantadine—Vomiting—Carmustine—melanoma	0.000195	0.00168	CcSEcCtD
Amantadine—Nausea—Dactinomycin—melanoma	0.000195	0.00167	CcSEcCtD
Amantadine—Rash—Carmustine—melanoma	0.000194	0.00166	CcSEcCtD
Amantadine—Nervous system disorder—Docetaxel—melanoma	0.000194	0.00166	CcSEcCtD
Amantadine—Dermatitis—Carmustine—melanoma	0.000193	0.00166	CcSEcCtD
Amantadine—Tachycardia—Docetaxel—melanoma	0.000193	0.00165	CcSEcCtD
Amantadine—Headache—Carmustine—melanoma	0.000192	0.00165	CcSEcCtD
Amantadine—Skin disorder—Docetaxel—melanoma	0.000192	0.00165	CcSEcCtD
Amantadine—Vomiting—Temozolomide—melanoma	0.000189	0.00162	CcSEcCtD
Amantadine—Anorexia—Docetaxel—melanoma	0.000188	0.00162	CcSEcCtD
Amantadine—Rash—Temozolomide—melanoma	0.000187	0.00161	CcSEcCtD
Amantadine—Dermatitis—Temozolomide—melanoma	0.000187	0.00161	CcSEcCtD
Amantadine—Headache—Temozolomide—melanoma	0.000186	0.0016	CcSEcCtD
Amantadine—Hypotension—Docetaxel—melanoma	0.000184	0.00158	CcSEcCtD
Amantadine—Nausea—Carmustine—melanoma	0.000182	0.00157	CcSEcCtD
Amantadine—Insomnia—Docetaxel—melanoma	0.000178	0.00153	CcSEcCtD
Amantadine—Paraesthesia—Docetaxel—melanoma	0.000177	0.00152	CcSEcCtD
Amantadine—Nausea—Temozolomide—melanoma	0.000176	0.00151	CcSEcCtD
Amantadine—Dyspnoea—Docetaxel—melanoma	0.000176	0.00151	CcSEcCtD
Amantadine—Somnolence—Docetaxel—melanoma	0.000175	0.00151	CcSEcCtD
Amantadine—Dyspepsia—Docetaxel—melanoma	0.000174	0.00149	CcSEcCtD
Amantadine—Decreased appetite—Docetaxel—melanoma	0.000172	0.00147	CcSEcCtD
Amantadine—Gastrointestinal disorder—Docetaxel—melanoma	0.00017	0.00146	CcSEcCtD
Amantadine—Fatigue—Docetaxel—melanoma	0.00017	0.00146	CcSEcCtD
Amantadine—Constipation—Docetaxel—melanoma	0.000169	0.00145	CcSEcCtD
Amantadine—Feeling abnormal—Docetaxel—melanoma	0.000163	0.0014	CcSEcCtD
Amantadine—Body temperature increased—Docetaxel—melanoma	0.000156	0.00134	CcSEcCtD
Amantadine—Hypersensitivity—Docetaxel—melanoma	0.000145	0.00125	CcSEcCtD
Amantadine—Asthenia—Docetaxel—melanoma	0.000142	0.00122	CcSEcCtD
Amantadine—Pruritus—Docetaxel—melanoma	0.00014	0.0012	CcSEcCtD
Amantadine—Diarrhoea—Docetaxel—melanoma	0.000135	0.00116	CcSEcCtD
Amantadine—Dizziness—Docetaxel—melanoma	0.00013	0.00112	CcSEcCtD
Amantadine—Vomiting—Docetaxel—melanoma	0.000125	0.00108	CcSEcCtD
Amantadine—Rash—Docetaxel—melanoma	0.000124	0.00107	CcSEcCtD
Amantadine—Dermatitis—Docetaxel—melanoma	0.000124	0.00107	CcSEcCtD
Amantadine—Headache—Docetaxel—melanoma	0.000124	0.00106	CcSEcCtD
Amantadine—Nausea—Docetaxel—melanoma	0.000117	0.00101	CcSEcCtD
Amantadine—DRD2—Signaling by GPCR—GAB2—melanoma	1.55e-05	0.000104	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GNA11—melanoma	1.55e-05	0.000104	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	1.55e-05	0.000103	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	1.54e-05	0.000103	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	1.52e-05	0.000101	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLCB4—melanoma	1.52e-05	0.000101	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SKI—melanoma	1.51e-05	0.0001	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR1—melanoma	1.51e-05	0.0001	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	1.5e-05	0.0001	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MC1R—melanoma	1.48e-05	9.9e-05	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—melanoma	1.47e-05	9.82e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CG—melanoma	1.47e-05	9.82e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT3—melanoma	1.47e-05	9.78e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	1.46e-05	9.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCR4—melanoma	1.46e-05	9.73e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—VCAN—melanoma	1.45e-05	9.69e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GNAQ—melanoma	1.44e-05	9.62e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC6A11—melanoma	1.43e-05	9.53e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIP4K2A—melanoma	1.43e-05	9.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR7—melanoma	1.42e-05	9.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GRM1—melanoma	1.42e-05	9.49e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—melanoma	1.42e-05	9.47e-05	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MAPK1—melanoma	1.4e-05	9.37e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	1.39e-05	9.3e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTAP—melanoma	1.39e-05	9.27e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	1.39e-05	9.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SUFU—melanoma	1.39e-05	9.25e-05	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—melanoma	1.37e-05	9.16e-05	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—melanoma	1.37e-05	9.15e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	1.36e-05	9.08e-05	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—melanoma	1.35e-05	9.03e-05	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—melanoma	1.34e-05	8.93e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT3—melanoma	1.33e-05	8.88e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	1.32e-05	8.84e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP17A1—melanoma	1.31e-05	8.78e-05	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—melanoma	1.31e-05	8.77e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	1.31e-05	8.75e-05	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MAPK1—melanoma	1.31e-05	8.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RHOB—melanoma	1.29e-05	8.63e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BCL2L11—melanoma	1.29e-05	8.63e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CD—melanoma	1.29e-05	8.63e-05	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—melanoma	1.28e-05	8.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	1.28e-05	8.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	1.28e-05	8.53e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—ALB—melanoma	1.28e-05	8.52e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	1.27e-05	8.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HDAC6—melanoma	1.24e-05	8.3e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNA11—melanoma	1.24e-05	8.29e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CG—melanoma	1.24e-05	8.26e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PHGDH—melanoma	1.24e-05	8.26e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LUM—melanoma	1.24e-05	8.26e-05	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—melanoma	1.24e-05	8.26e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—EDN1—melanoma	1.23e-05	8.22e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP17A1—melanoma	1.23e-05	8.18e-05	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ALB—melanoma	1.22e-05	8.12e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—FASN—melanoma	1.21e-05	8.11e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HPSE—melanoma	1.21e-05	8.1e-05	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—melanoma	1.21e-05	8.09e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CSF2—melanoma	1.2e-05	8.03e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC5A5—melanoma	1.19e-05	7.98e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—melanoma	1.19e-05	7.97e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CUBN—melanoma	1.19e-05	7.95e-05	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—melanoma	1.18e-05	7.89e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR2—melanoma	1.18e-05	7.86e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—melanoma	1.18e-05	7.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAC2—melanoma	1.16e-05	7.74e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNA11—melanoma	1.16e-05	7.72e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNAQ—melanoma	1.15e-05	7.7e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CD44—melanoma	1.15e-05	7.7e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	1.15e-05	7.7e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PRKCA—melanoma	1.15e-05	7.7e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SDHD—melanoma	1.15e-05	7.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BSG—melanoma	1.15e-05	7.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CSPG4—melanoma	1.15e-05	7.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—WNT5A—melanoma	1.14e-05	7.62e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFC—melanoma	1.14e-05	7.62e-05	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ALB—melanoma	1.13e-05	7.57e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—FASN—melanoma	1.13e-05	7.56e-05	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—melanoma	1.13e-05	7.52e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CB—melanoma	1.13e-05	7.52e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EDN1—melanoma	1.12e-05	7.46e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—melanoma	1.12e-05	7.45e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPAM—melanoma	1.11e-05	7.44e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—melanoma	1.11e-05	7.44e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1B1—melanoma	1.11e-05	7.39e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CSF2—melanoma	1.09e-05	7.29e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	1.09e-05	7.29e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CD—melanoma	1.09e-05	7.26e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNAQ—melanoma	1.08e-05	7.18e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CD44—melanoma	1.08e-05	7.18e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALB—melanoma	1.07e-05	7.17e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—RAC1—melanoma	1.07e-05	7.14e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	1.06e-05	7.09e-05	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—melanoma	1.05e-05	7.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PRKCA—melanoma	1.05e-05	6.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	1.04e-05	6.93e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	1.04e-05	6.93e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1B1—melanoma	1.03e-05	6.88e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAP2K2—melanoma	1.02e-05	6.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—F2R—melanoma	1e-05	6.69e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	9.89e-06	6.6e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	9.81e-06	6.55e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—melanoma	9.74e-06	6.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RAC1—melanoma	9.71e-06	6.48e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EDNRB—melanoma	9.7e-06	6.48e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CB—melanoma	9.48e-06	6.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLA2G6—melanoma	9.48e-06	6.33e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTK2B—melanoma	9.42e-06	6.29e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—melanoma	9.4e-06	6.27e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNA11—melanoma	9.16e-06	6.12e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GAB2—melanoma	9.16e-06	6.12e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FLT1—melanoma	9.12e-06	6.09e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—melanoma	9.11e-06	6.08e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—melanoma	9.03e-06	6.03e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	9.01e-06	6.02e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	8.72e-06	5.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR4—melanoma	8.61e-06	5.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FOXO4—melanoma	8.61e-06	5.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HDAC2—melanoma	8.61e-06	5.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNAQ—melanoma	8.52e-06	5.69e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—VCAN—melanoma	8.51e-06	5.68e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—melanoma	8.49e-06	5.67e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PRKCA—melanoma	8.38e-06	5.6e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ERCC2—melanoma	8.32e-06	5.55e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—melanoma	8.2e-06	5.48e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—melanoma	8.19e-06	5.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SYK—melanoma	8.01e-06	5.35e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CD—melanoma	7.94e-06	5.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NGFR—melanoma	7.86e-06	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ITGAV—melanoma	7.86e-06	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT3—melanoma	7.86e-06	5.25e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PRKCA—melanoma	7.82e-06	5.22e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ERCC2—melanoma	7.75e-06	5.17e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	7.36e-06	4.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SOCS1—melanoma	7.28e-06	4.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAP2K1—melanoma	7.26e-06	4.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—S100B—melanoma	7.26e-06	4.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CD—melanoma	7.21e-06	4.82e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP17A1—melanoma	7.18e-06	4.79e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB4—melanoma	6.94e-06	4.63e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CB—melanoma	6.92e-06	4.62e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN2B—melanoma	6.88e-06	4.59e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—melanoma	6.87e-06	4.59e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNA11—melanoma	6.78e-06	4.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD86—melanoma	6.66e-06	4.44e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—melanoma	6.65e-06	4.44e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	6.65e-06	4.44e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—FASN—melanoma	6.64e-06	4.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EDN1—melanoma	6.6e-06	4.41e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—melanoma	6.57e-06	4.38e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—melanoma	6.53e-06	4.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CSF2—melanoma	6.45e-06	4.31e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF1—melanoma	6.45e-06	4.31e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—melanoma	6.36e-06	4.24e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—melanoma	6.34e-06	4.23e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—E2F1—melanoma	6.32e-06	4.22e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNAQ—melanoma	6.3e-06	4.21e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CD44—melanoma	6.3e-06	4.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CB—melanoma	6.29e-06	4.2e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRA—melanoma	6.25e-06	4.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCA—melanoma	6.19e-06	4.13e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ITGB3—melanoma	6.19e-06	4.13e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—melanoma	6.12e-06	4.09e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPP1—melanoma	6.07e-06	4.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAP2K2—melanoma	6.05e-06	4.04e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1B1—melanoma	6.04e-06	4.04e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—melanoma	6.04e-06	4.03e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—melanoma	5.91e-06	3.94e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—melanoma	5.78e-06	3.86e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CD—melanoma	5.77e-06	3.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—melanoma	5.77e-06	3.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—melanoma	5.75e-06	3.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAC1—melanoma	5.74e-06	3.83e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALB—melanoma	5.7e-06	3.81e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—melanoma	5.61e-06	3.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIF1A—melanoma	5.5e-06	3.67e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CD—melanoma	5.38e-06	3.59e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALB—melanoma	5.31e-06	3.55e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KDR—melanoma	5.26e-06	3.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FN1—melanoma	5.06e-06	3.38e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CB—melanoma	5.03e-06	3.36e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—melanoma	4.99e-06	3.33e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH1—melanoma	4.96e-06	3.31e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD80—melanoma	4.86e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APC—melanoma	4.85e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—melanoma	4.85e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KIT—melanoma	4.85e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—melanoma	4.85e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGF—melanoma	4.79e-06	3.2e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—melanoma	4.72e-06	3.15e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CB—melanoma	4.69e-06	3.13e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—melanoma	4.65e-06	3.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK3—melanoma	4.64e-06	3.1e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PRKCA—melanoma	4.58e-06	3.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—melanoma	4.56e-06	3.04e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ERCC2—melanoma	4.54e-06	3.03e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—melanoma	4.44e-06	2.96e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK1—melanoma	4.42e-06	2.95e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—melanoma	4.42e-06	2.95e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—melanoma	4.35e-06	2.9e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAP2K1—melanoma	4.29e-06	2.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CD—melanoma	4.26e-06	2.84e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—melanoma	4.22e-06	2.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—melanoma	4.17e-06	2.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF2—melanoma	4.08e-06	2.72e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—melanoma	4.05e-06	2.71e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—melanoma	3.83e-06	2.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—melanoma	3.82e-06	2.55e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—melanoma	3.76e-06	2.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CB—melanoma	3.71e-06	2.48e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—melanoma	3.59e-06	2.4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—melanoma	3.57e-06	2.38e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—melanoma	3.55e-06	2.37e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1B—melanoma	3.49e-06	2.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—melanoma	3.46e-06	2.31e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—melanoma	3.45e-06	2.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—melanoma	3.42e-06	2.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—melanoma	3.41e-06	2.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—melanoma	3.39e-06	2.27e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—melanoma	3.32e-06	2.22e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—melanoma	3.29e-06	2.2e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—melanoma	3.23e-06	2.15e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—melanoma	3.22e-06	2.15e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—melanoma	3.21e-06	2.14e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NFKB1—melanoma	3.19e-06	2.13e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CD—melanoma	3.15e-06	2.11e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—melanoma	3.13e-06	2.09e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALB—melanoma	3.11e-06	2.08e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—melanoma	3.07e-06	2.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—melanoma	2.9e-06	1.94e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—melanoma	2.87e-06	1.92e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—melanoma	2.86e-06	1.91e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—melanoma	2.86e-06	1.91e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CB—melanoma	2.75e-06	1.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK3—melanoma	2.74e-06	1.83e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—melanoma	2.72e-06	1.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—melanoma	2.67e-06	1.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK1—melanoma	2.61e-06	1.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—melanoma	2.61e-06	1.74e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—melanoma	2.51e-06	1.67e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—melanoma	2.46e-06	1.65e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—melanoma	2.38e-06	1.59e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—melanoma	2.34e-06	1.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—melanoma	2.26e-06	1.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—melanoma	2.19e-06	1.46e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—melanoma	2.09e-06	1.4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—melanoma	2e-06	1.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—melanoma	1.85e-06	1.23e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—melanoma	1.68e-06	1.12e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—melanoma	1.37e-06	9.14e-06	CbGpPWpGaD
